Psychopharmakotherapie griffbereit Medikamente, psychoaktive Genussmittel und Drogen
Gespeichert in:
1. Verfasser: | |
---|---|
Format: | Buch |
Sprache: | German |
Veröffentlicht: |
Stuttgart
Schattauer
[2016]
|
Ausgabe: | 2., vollständig aktualisierte und erweiterte Auflage |
Schriftenreihe: | griffbereit
|
Schlagworte: | |
Online-Zugang: | Inhaltsverzeichnis |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
MARC
LEADER | 00000nam a2200000 c 4500 | ||
---|---|---|---|
001 | BV043376770 | ||
003 | DE-604 | ||
005 | 20160915 | ||
007 | t| | ||
008 | 160218s2016 xx a||| |||| 00||| ger d | ||
015 | |a 15,N51 |2 dnb | ||
016 | 7 | |a 1079863125 |2 DE-101 | |
020 | |a 3794531833 |9 3-7945-3183-3 | ||
020 | |a 9783794531837 |c : ca. EUR 25.70 (AT), ca. EUR 24.99 (DE) |9 978-3-7945-3183-7 | ||
024 | 3 | |a 9783794531837 | |
035 | |a (OCoLC)956474717 | ||
035 | |a (DE-599)DNB1079863125 | ||
040 | |a DE-604 |b ger |e rda | ||
041 | 0 | |a ger | |
049 | |a DE-355 |a DE-1052 |a DE-70 |a DE-11 |a DE-M483 |a DE-824 |a DE-1949 |a DE-19 |a DE-128 | ||
082 | 0 | |a 610 |2 23 | |
084 | |a CZ 2000 |0 (DE-625)19239: |2 rvk | ||
084 | |a XI 5803 |0 (DE-625)153018:12909 |2 rvk | ||
084 | |a 610 |2 sdnb | ||
084 | |a QV 77 |2 nlm | ||
100 | 1 | |a Dreher, Jan |d 1971- |e Verfasser |0 (DE-588)120465655 |4 aut | |
245 | 1 | 0 | |a Psychopharmakotherapie griffbereit |b Medikamente, psychoaktive Genussmittel und Drogen |c Jan Dreher |
250 | |a 2., vollständig aktualisierte und erweiterte Auflage | ||
264 | 1 | |a Stuttgart |b Schattauer |c [2016] | |
264 | 4 | |c © 2016 | |
300 | |a XIV, 267 Seiten |b 10 Illustrationen, Diagramme |c 18.5 cm x 12 cm | ||
336 | |b txt |2 rdacontent | ||
337 | |b n |2 rdamedia | ||
338 | |b nc |2 rdacarrier | ||
490 | 0 | |a griffbereit | |
650 | 2 | |a Mental Disorders - drug therapy | |
650 | 2 | |a Psychotropic Drugs - therapeutic use | |
650 | 0 | 7 | |a Psychopharmakotherapie |0 (DE-588)4236424-3 |2 gnd |9 rswk-swf |
653 | |a Ärzte in Weiterbildung zum Facharzt für Psychiatrie und Psychotherapie; Haus- und Allgemeinärzte; andere Ärzte, die immer wieder mal mit Psychopharmakologie zu tun haben; Medizinstudenten; Psychologen in Ausbildung (speziell Psychologen in Weiterbildung zum Psychologischen Psychotherapeuten); Pflegekräfte auf psychiatrischen Stationen; Sozialarbeiter, die in einer psychiatrischen Klinik tätig sind; Betroffene und Angehörige | ||
653 | |a ADHS-Therapeutika | ||
653 | |a Acetylcholinesterasehemmer | ||
653 | |a extrapyramidalmotorische Störungen | ||
689 | 0 | 0 | |a Psychopharmakotherapie |0 (DE-588)4236424-3 |D s |
689 | 0 | |5 DE-604 | |
710 | 2 | |a Schattauer GmbH |0 (DE-588)1065173687 |4 pbl | |
776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe, EPUB |z 978-3-7945-9041-4 |
776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe, PDF |z 978-3-7945-9011-7 |
856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=028795572&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-028795572 |
Datensatz im Suchindex
DE-19_call_number | 0760/8 Med.G 9667 |
---|---|
DE-19_location | 55 |
DE-BY-UBM_katkey | 5335121 |
DE-BY-UBM_media_number | 99995551486 |
DE-BY-UBR_call_number | 00/CZ 2000 D771(2) 86/VS 7150 D771(2) |
DE-BY-UBR_katkey | 5724783 |
DE-BY-UBR_location | 00 86 |
DE-BY-UBR_media_number | 069039677189 069041598166 |
_version_ | 1823056011599020032 |
adam_text | INHALT
A N L E I T U N G
...........................................................................................................
1
1 PSYCHOPHARMAKA *M UE BERBLICK....................................... 5
1.1 WAHL DES P SYCHOPHARM
AKONS......................................................... 6
1.2 W IRKUNG DER N E U RO TRA N S M ITTE
R....................................................... 8
1.3 VERORDNUNGSHAEUFIGKEIT DER PSYCHOPHARMAKA . . . . . . . . . . . . **
2 ANTIDEPRESSIVA
..................................................................
13
2.1 E IN TE ILU N G
................................................................................................
13
2.2 G E S C H IC H TE
.............................................................................................
14
2.3 W IRK P RIN Z IP IE N
.......................................................................................
14
2.4 T H E RA P IE
..................................................................................................
16
2.4.1
DEPRESSION................................................................................................
16
2.4.2
ANGSTSTOERUNGEN.......................................................................................
20
SNRI,
SSRI..................................................................................................
20
P
REGABALIN................................................................................................
21
BENZODIAZEPINE.......................................................................................
21
2.4.3 ZWANGSERKRANKUNGEN
.............................................................................
23
2.4.4 SOMATOFORME
STORUNGEN.......................................................................
26
PSYCHOTHERAPIE.........................................................................................
26
SNRI, SSRI ODER TRIZYKLIKA
.................................................................. 26
SCHMERZBEHANDLUNG................................................................................
27
BENZODIAZEPINE.......................................................................................
28
2.5 W IRKS TO FFKLA S S E N
.................................................................................
28
2.5.1 SSRI
...........................................................................................................
28
2.5.2 S N R
L...........................................................................................................
29
2.5.3 N A R
I...........................................................................................................
29
2.5.4 TRI UND TETRAZYKLISCHE ANTID^^
................................................ 30
2.5.5 ***-H E M M
ER.........................................................................................
30
2.6 W IR K S T O F F E
.............................................................................................
32
2.6.1 CITALOPRAM
................................................................................................
32
2.6.2 ESCITALOPRAM
.............................................................................................
36
2.6.3 VENLAFAXIN
................................................................................................
39
2.6.4 D
ULOXETIN..................................................................................................
41
2.6.5
VORFIOXETIN................................................................................................
43
2.6.6 M IRTAZAP JN
................................................................................................
46
2.6.7
AGOMELATIN................................................................................................
48
2 .6 3 AMITRIPTYLIN
............................................................................................
51
2.6.9 M O C L O B E M I D . . . . . . . . . . . . . . . . 53
2.7 N EB EN W IRKU N G EN
..................................................................................
55
2.7.1
SEROTONINSYNDROM..................................................................................
55
2.7.2 ANTIDEPRESSIVA UND SUIZIDALITAET
...........................................................
57
2.7.3 ABSETZERSCHEINUNGEN
.............................................................................
58
2.8 WELCHES ANTIDEPRESSIVUM GEBE CH WEM? . . . . . . . . . . . . . . .
59
3 N E U R O LE P T IK A
......................................................................................
63
3.1 E IN TE ILU N G
................................................................................................
64
3.1.1 CHEMSCHE S TRU KTU
R................................................................................
64
3.1.2 NEUROLEPTISCHE
POTENZ...........................................................................
65
3.1.3 UNTERSCHIEDLICHE NEBENW IRK
....................................................
65
TYPIKA.........................................................................................................
65
ATYPJKA.......................................................................................................
66
3.2 G E S C H IC H TE
............................................................................................
67
3.3 A N TIP SYCH
OTIKA......................................................................................
69
3.3.1 W
IRKPRINZIPIEN.........................................................................................
69
3 3 .2
REZEPTORBINDUNGSPROFILE.......................................................................
70
3 3 .3
THERAPIE....................................................................................................
76
PSYCHOSE....................................................................................................
76
DEL
*
.........................................................................
. . . . . . . . .. 78
WAHNHAFTE
DEPRESSION...........................................................................
78
3 3 .4 EXKURS: DIE
CATIE-STUDIE.......................................................................
79
3.3.5 WIRKSTOFFE
.............................................................. 81
BENPERIDOL UND
HALOPERIDOL..................................................................
81
RJSPERIDON
................................................................................................
83
OLANZAPIN..................................................................................................
85
ARIPIPRAZOL................................................................................................
88
AM
ISULPRID................................................................................................
91
Q
UETIAPIN..................................................................................................
93
ZIPRASIDON
................................................................................................
97
SERTINDOL....................................................................................................
100
CLOZAPIN....................................................................................................
103
3 3 .6
DEPOTNEUROLEPTIKA.................................................................................
108
3.3.7 WELCHES ANTIPSYCHOTIKUMGEFE 112
3.4 S E D A TIV A
..................................................................................................
116
3.4.1 PROMETHAZIN
.............................................................................................
116
3.4.2 OP*PRAMOL
................................................................................................
118
3.5 A N TIH Y P E RK IN E TIK A
................................................................................
120
3.5.1 T IA P RLD
.......................................................................................................
120
3.6 N E B E N -U N D W E C H S E LW IRK U N G E N
....................................................
123
3.6.1 EXTRAPYRAMIDALMOTORISCHE STORUNGEN ( E P M S ) . . . . . . . . . .
. . . . . . 123
3.6.2 AKATHISIE
..................................................................................................
124
3 .6 3 METABOLISCHES
SYNDROM........................................................................
125
BAUCHUMFANG ALS LEITKRITERIUM
...........................................................
126
3 6 .4
AGRANULOZYTOSE.....................................................................................
128
3.6.5 QTC-ZEIT-VERLAENGERUNG
...........................................................................
130
4 P H A S E N P R O P H Y LA K TIK A
....................................................................
134
4.1 P
HASENPROPHYLAXE..................................................................................
135
4.2 T H E RA P IE
....................................................................................................
136
4.2.1 MANISCHE EPISODE
....................................................................................
136
4.2.2 DEPRESSIVE EPISODE
..................................................................................
137
4.3 W IR K S T O F F E
...............................................................................................
138
4.3.1
LITHIUM........................................................................................................
138
4.3.2
VALPROINSAEURE.............................................................................................
143
4.3.3 CARBAMAZEPIN
...........................................................................................
147
4.3.4 LAM
OTRIGIN..................................................................................................
151
5 A N X IO LY T IK A
.............................................................................................
153
5.1 N EUROLEPTANXIOLYSE
.............................................................................
153
5.2 B EN ZO D IAZEP IN
E......................................................................................
154
5.2.1
AQUIVALENZDOSIERUNGEN...........................................................................
155
5.2.2
NEBENWIRKUNGEN......................................................................................
157
5.2.3 WIRKSTOFFE
..................................................................................................
157
DIAZEPAM
....................................................................................................
157
LORAZEPAM..................................................................................................
160
6 S C H LA F M IT T E
L...........................................................................................
163
6.1 DOXYLAM JN
...............................................................................................
164
6.2 DIE
Z*SUBSTANZEN....................................................................................
165
6.2.1 ZOLPIDEM
....................................................................................................
166
6.2.2
ZOPICLON.....................................................................................................
168
7 A D H S *T H E R A P E U T IK A
...........................................................................
170
7.1 A TOM OXETIN
.............................................................................................
170
7.2 M E TH Y LP H E N ID A
T......................................................................................
172
8 G E N U S S M ITTE
L.......................................................................................
178
8.1 A LK O H O
L....................................................................................................
178
8.2 NICOTIN
..............................................................................................
185
8.3 C O FF E IN
....................................................................................................
189
9 ILLE G A LE D R O G E N
....................................................................................
193
9.1 H E RO IN
......................................................................................................
195
9.2 C O C A IN
......................................................................................................
208
9.2.1 COCAIN(HYDROCHLORID)
.............................................................................
210
9.2.2 C R A C K
......................................................................................................
210
9.3 A M P H E TA M IN E
.....................................................................................
212
9.3.1 AMPHETAMIN: SPEED,
PEP.......................................................................
216
9.3.2 M D M A
.......................................................................................................
217
9.3.3 METHAMPHETAMIN
....................................................................................
217
9.4 C ANN
ABIS..................................................................................................
219
9.5 G AM M A-H YDROXYBUTTERSAEURE
......................................................... 222
10 G E R O N TO P S Y C H IA TR IE
.........................................................................
224
10.1 WASSER
....................................................................................................
224
10.2 EINDOSIERUNG VON M ED IKAM ENT
..................................................
226
10.3 THERAPIE DES DELIRS M A L T E R
...........................................................
228
10.4 A N TID E M E N TIV A
.......................................................................................
229
10.4.1 *
NTEJLUNG..................................................................................................
229
10.4.2 W
*
KPRNZPEN....................................................................................*
230
ACETYLCHOLINESTERASEHEMMER................................................................
230
NMDA_ANTAGONST..................................................................................
231
10.4.3
THERAPIE....................................................................................................
231
M OBUS A LZHEIM
ER..................................................................................
231
GEMACHTE
DEMENZ..................................................................................
233
VASKULAERE D EM EN
Z..................................................................................
233
FRONTOTEMPORAL
DEMENZ.......................................................................
233
PARKINSON-DEMENZ..................................................................................
233
LEWY-KORPERCHEN-DEMENZ
....................................................................
234
10.4.4 WIRKSTOFFE
................................................................................................
234
GALANTAMIN................................................................................................
234
DONEPEZIL..................................................................................................
235
RIVASTJGMJN................................................................................................
236
M EM
ANTIN..................................................................................................
237
10.4.5 NEBENWIRKUNGEN
....................................................................................
238
11 N O T F AE L L E
..................................................................................................
240
111 PHARM AKOTHERAPIE DES ERREGUNGSZUSTANDES . . . . . . . . . . . . .
240
* 2 S U IZ ID A LITAE
T..............................................................................................
245
12 M E D IK A M E N TE N W E C H S E LW IR K U N G E N . . . . . . . . .
. . . . . . . . . . 247
G LO SSAR
................................................................................................................
249
S A C H V E R Z E IC H N IS
.............................................................................................
256
|
any_adam_object | 1 |
author | Dreher, Jan 1971- |
author_GND | (DE-588)120465655 |
author_facet | Dreher, Jan 1971- |
author_role | aut |
author_sort | Dreher, Jan 1971- |
author_variant | j d jd |
building | Verbundindex |
bvnumber | BV043376770 |
classification_rvk | CZ 2000 XI 5803 |
ctrlnum | (OCoLC)956474717 (DE-599)DNB1079863125 |
dewey-full | 610 |
dewey-hundreds | 600 - Technology (Applied sciences) |
dewey-ones | 610 - Medicine and health |
dewey-raw | 610 |
dewey-search | 610 |
dewey-sort | 3610 |
dewey-tens | 610 - Medicine and health |
discipline | Psychologie Medizin |
edition | 2., vollständig aktualisierte und erweiterte Auflage |
format | Book |
fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02643nam a2200553 c 4500</leader><controlfield tag="001">BV043376770</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20160915 </controlfield><controlfield tag="007">t|</controlfield><controlfield tag="008">160218s2016 xx a||| |||| 00||| ger d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">15,N51</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1079863125</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3794531833</subfield><subfield code="9">3-7945-3183-3</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783794531837</subfield><subfield code="c">: ca. EUR 25.70 (AT), ca. EUR 24.99 (DE)</subfield><subfield code="9">978-3-7945-3183-7</subfield></datafield><datafield tag="024" ind1="3" ind2=" "><subfield code="a">9783794531837</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)956474717</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1079863125</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">ger</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield><subfield code="a">DE-1052</subfield><subfield code="a">DE-70</subfield><subfield code="a">DE-11</subfield><subfield code="a">DE-M483</subfield><subfield code="a">DE-824</subfield><subfield code="a">DE-1949</subfield><subfield code="a">DE-19</subfield><subfield code="a">DE-128</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">CZ 2000</subfield><subfield code="0">(DE-625)19239:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 5803</subfield><subfield code="0">(DE-625)153018:12909</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">610</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">QV 77</subfield><subfield code="2">nlm</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Dreher, Jan</subfield><subfield code="d">1971-</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)120465655</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Psychopharmakotherapie griffbereit</subfield><subfield code="b">Medikamente, psychoaktive Genussmittel und Drogen</subfield><subfield code="c">Jan Dreher</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">2., vollständig aktualisierte und erweiterte Auflage</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Stuttgart</subfield><subfield code="b">Schattauer</subfield><subfield code="c">[2016]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">© 2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XIV, 267 Seiten</subfield><subfield code="b">10 Illustrationen, Diagramme</subfield><subfield code="c">18.5 cm x 12 cm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">griffbereit</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Mental Disorders - drug therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Psychotropic Drugs - therapeutic use</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Psychopharmakotherapie</subfield><subfield code="0">(DE-588)4236424-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Ärzte in Weiterbildung zum Facharzt für Psychiatrie und Psychotherapie; Haus- und Allgemeinärzte; andere Ärzte, die immer wieder mal mit Psychopharmakologie zu tun haben; Medizinstudenten; Psychologen in Ausbildung (speziell Psychologen in Weiterbildung zum Psychologischen Psychotherapeuten); Pflegekräfte auf psychiatrischen Stationen; Sozialarbeiter, die in einer psychiatrischen Klinik tätig sind; Betroffene und Angehörige</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ADHS-Therapeutika</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Acetylcholinesterasehemmer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">extrapyramidalmotorische Störungen</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Psychopharmakotherapie</subfield><subfield code="0">(DE-588)4236424-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">Schattauer GmbH</subfield><subfield code="0">(DE-588)1065173687</subfield><subfield code="4">pbl</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe, EPUB</subfield><subfield code="z">978-3-7945-9041-4</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe, PDF</subfield><subfield code="z">978-3-7945-9011-7</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=028795572&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-028795572</subfield></datafield></record></collection> |
id | DE-604.BV043376770 |
illustrated | Illustrated |
indexdate | 2025-02-03T17:41:49Z |
institution | BVB |
institution_GND | (DE-588)1065173687 |
isbn | 3794531833 9783794531837 |
language | German |
oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-028795572 |
oclc_num | 956474717 |
open_access_boolean | |
owner | DE-355 DE-BY-UBR DE-1052 DE-70 DE-11 DE-M483 DE-824 DE-1949 DE-19 DE-BY-UBM DE-128 |
owner_facet | DE-355 DE-BY-UBR DE-1052 DE-70 DE-11 DE-M483 DE-824 DE-1949 DE-19 DE-BY-UBM DE-128 |
physical | XIV, 267 Seiten 10 Illustrationen, Diagramme 18.5 cm x 12 cm |
publishDate | 2016 |
publishDateSearch | 2016 |
publishDateSort | 2016 |
publisher | Schattauer |
record_format | marc |
series2 | griffbereit |
spellingShingle | Dreher, Jan 1971- Psychopharmakotherapie griffbereit Medikamente, psychoaktive Genussmittel und Drogen Mental Disorders - drug therapy Psychotropic Drugs - therapeutic use Psychopharmakotherapie (DE-588)4236424-3 gnd |
subject_GND | (DE-588)4236424-3 |
title | Psychopharmakotherapie griffbereit Medikamente, psychoaktive Genussmittel und Drogen |
title_auth | Psychopharmakotherapie griffbereit Medikamente, psychoaktive Genussmittel und Drogen |
title_exact_search | Psychopharmakotherapie griffbereit Medikamente, psychoaktive Genussmittel und Drogen |
title_full | Psychopharmakotherapie griffbereit Medikamente, psychoaktive Genussmittel und Drogen Jan Dreher |
title_fullStr | Psychopharmakotherapie griffbereit Medikamente, psychoaktive Genussmittel und Drogen Jan Dreher |
title_full_unstemmed | Psychopharmakotherapie griffbereit Medikamente, psychoaktive Genussmittel und Drogen Jan Dreher |
title_short | Psychopharmakotherapie griffbereit |
title_sort | psychopharmakotherapie griffbereit medikamente psychoaktive genussmittel und drogen |
title_sub | Medikamente, psychoaktive Genussmittel und Drogen |
topic | Mental Disorders - drug therapy Psychotropic Drugs - therapeutic use Psychopharmakotherapie (DE-588)4236424-3 gnd |
topic_facet | Mental Disorders - drug therapy Psychotropic Drugs - therapeutic use Psychopharmakotherapie |
url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=028795572&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
work_keys_str_mv | AT dreherjan psychopharmakotherapiegriffbereitmedikamentepsychoaktivegenussmittelunddrogen AT schattauergmbh psychopharmakotherapiegriffbereitmedikamentepsychoaktivegenussmittelunddrogen |